Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2010

01-05-2010 | Preclinical study

Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer

Authors: Einar Gudlaugsson, Ivar Skaland, Emiel A. M. Janssen, Paul J. van Diest, Feja J. Voorhorst, Kjell Kjellevold, Axel zur Hausen, Jan P. A. Baak

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Login to get access

Abstract

Evaluation of prognostic factors in lymph node negative (LNneg) invasive lobular cancers (ILCs). Prospective analysis of proliferation and other prognosticators in 121 LNneg ILCs (119 months median follow-up, range 19–181), without adjuvant chemotherapy. ILC subtype was assessed in accordance with WHO-2003 criteria. Immunohistochemical E-cadherin and estrogen receptor were used. With a median follow up time of 83 months (range 19–181), 30 of the 121 (25%) ILC patients developed distant metastases and 27 (22%) died. None of the cases classified as solid/pleomorphic lobular were E-cadherin or estrogen receptor positive, contrasting the other ILCs. The solid/alveolar ILCs (n = 17) had a worse survival (50%) than the other ILCs (n = 104; 83%, P < 0.0001). Mitotic activity index (MAI) (but not nuclear grade or tubule formation) was prognostic with a threshold 0–5 versus >5 (=MAI-5) (contrasting MAI < 10 vs. ≥10 in breast cancers in general; 85 and 54% survival, P < 0.0001). In multivariate analysis only subtype and MAI but none of the other characteristics had independent prognostic value. Histologic subtype and MAI have independent prognostic value in node negative invasive lobular cancers.
Literature
1.
go back to reference Ellis IO, Schnitt SJ, Sastre-Garau X (2003) Invasive breast carcinoma. In: Tavassoli FA, Devilee P et al (eds) Pathology and genetics of tumours of the breast and female genital organs: WHO classification of tumours series. IARC press, Lyon, pp 13–48 Ellis IO, Schnitt SJ, Sastre-Garau X (2003) Invasive breast carcinoma. In: Tavassoli FA, Devilee P et al (eds) Pathology and genetics of tumours of the breast and female genital organs: WHO classification of tumours series. IARC press, Lyon, pp 13–48
5.
go back to reference Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:R149–R156. doi:10.1186/bcr767 CrossRefPubMed Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:R149–R156. doi:10.​1186/​bcr767 CrossRefPubMed
6.
go back to reference Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M et al (2005) Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 207:1–13. doi:10.1002/path.1806 CrossRefPubMed Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M et al (2005) Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 207:1–13. doi:10.​1002/​path.​1806 CrossRefPubMed
7.
go back to reference Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB et al (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23(25):5993–6001. doi:10.1200/JCO.2005.05.511 CrossRefPubMed Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB et al (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23(25):5993–6001. doi:10.​1200/​JCO.​2005.​05.​511 CrossRefPubMed
8.
go back to reference Baak JP, van Diest PJ, Janssen EA et al (2008) Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Ann Oncol 19(4):649–654. doi:10.1093/annonc/mdm535 CrossRefPubMed Baak JP, van Diest PJ, Janssen EA et al (2008) Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Ann Oncol 19(4):649–654. doi:10.​1093/​annonc/​mdm535 CrossRefPubMed
9.
go back to reference McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker studies. J Clin Oncol 23(36):9067–9072CrossRefPubMed McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker studies. J Clin Oncol 23(36):9067–9072CrossRefPubMed
10.
go back to reference Baak JPA, Snijders W, van Diermen B et al (2003) Prospective multicenter validation confirms the prognostic superiority of the ECPI in FIGO-1 endometrial carcinoma. J Clin Oncol 23:4214–4221. doi:10.1200/JCO.2003.02.087 CrossRef Baak JPA, Snijders W, van Diermen B et al (2003) Prospective multicenter validation confirms the prognostic superiority of the ECPI in FIGO-1 endometrial carcinoma. J Clin Oncol 23:4214–4221. doi:10.​1200/​JCO.​2003.​02.​087 CrossRef
11.
go back to reference Jannink I, Bennen JN, Blaauw J et al (1995) At convenience and systematic random sampling: effects on the prognostic value of nuclear area assessments in breast cancer patients. Breast Cancer Res Treat 36:55–60. doi:10.1007/BF00690185 CrossRefPubMed Jannink I, Bennen JN, Blaauw J et al (1995) At convenience and systematic random sampling: effects on the prognostic value of nuclear area assessments in breast cancer patients. Breast Cancer Res Treat 36:55–60. doi:10.​1007/​BF00690185 CrossRefPubMed
12.
go back to reference Fleege JC, van Diest PJ, Baak JPA (1993) Systematic random sampling for selective interactive nuclear morphometry in breast cancer sections. Refinement and multiobserver evaluation. Anal Quant Cytol Histol 15:281–289PubMed Fleege JC, van Diest PJ, Baak JPA (1993) Systematic random sampling for selective interactive nuclear morphometry in breast cancer sections. Refinement and multiobserver evaluation. Anal Quant Cytol Histol 15:281–289PubMed
13.
go back to reference Skaland I, van Diest PJ, Janssen EAM et al (2008) Prognostic differences of WHO-assessed mitotic activity index (MAI) and mitotic impression by quick scanning in invasive ductal breast cancer patients under 55 years of age. Hum Pathol 39(4):584–590. doi:10.1016/j.humpath.2007.08.016 CrossRefPubMed Skaland I, van Diest PJ, Janssen EAM et al (2008) Prognostic differences of WHO-assessed mitotic activity index (MAI) and mitotic impression by quick scanning in invasive ductal breast cancer patients under 55 years of age. Hum Pathol 39(4):584–590. doi:10.​1016/​j.​humpath.​2007.​08.​016 CrossRefPubMed
14.
go back to reference Rakha EA, El-Sayed ME, Menon S et al (2008) Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 111(1):121–127 (Epub 2007 Oct 11)CrossRefPubMed Rakha EA, El-Sayed ME, Menon S et al (2008) Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 111(1):121–127 (Epub 2007 Oct 11)CrossRefPubMed
Metadata
Title
Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer
Authors
Einar Gudlaugsson
Ivar Skaland
Emiel A. M. Janssen
Paul J. van Diest
Feja J. Voorhorst
Kjell Kjellevold
Axel zur Hausen
Jan P. A. Baak
Publication date
01-05-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0442-x

Other articles of this Issue 1/2010

Breast Cancer Research and Treatment 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine